BioSenic S.A. announced that it has entered into new subscription agreement with returning investor 120 unsecured, subordinated, registered convertible bonds at an issue price of 10,000 for the gross proceeds of ?1,200,000 on January 8, 2024. The transaction is expected to receive in 4 tranches of ? 300,000 convertible debentures each. The CBs, denominated ? 10,000 each, will be in the form of unsecured, subordinated, registered bonds. The CBs will not bear any coupon and have a maturity date of five years after issuance, which may be extended by up to a year if the automatic conversion of the CBs upon the maturity date would otherwise result in GTO 15 holding more than 24.9% of the company's voting shares. The CBs are convertible into ordinary shares of company The conversion price will be equal to 95% of the lowest daily VWAP (Volume-Weighted Average Price) of the ordinary shares of company observed during the pricing period of ten consecutive trading days expiring on the trading day immediately preceding the date of CB holder?s request of conversion, it being agreed that any trading day where the CB holder participates in more than 25% of the daily trading volume will be excluded from the 10-day pricing period.

On the same date, the company announced that it has received 30 convertible debentures at an issue price of ?10,000 each for the gross proceeds of ?300,000 in the first tranche.